Quick answer
EHL BIO has signed an MOU with Wonkwang University Hospital to promote regenerative medicine research, focusing on using stem cells and immune cells to treat rare and intractable diseases, aiming to lead the Korean regenerative medicine market.
Key takeaways
- Partnership signed on September 6, 2022, for collaborative clinical research.
- Focused on treating rare and incurable diseases through innovative cell therapies.
- Combines the hospital's clinical expertise with EHL BIO's advanced cell culture technology.
- Strengthening leadership in South Korea's regenerative medicine market.
A Milestone in Regenerative Medicine Collaboration
On September 6, 2022, EHL BIO officially signed a partnership agreement with Wonkwang University Hospital to establish a collaborative network for advanced regenerative medicine research. This partnership is a key step in applying new technologies to a wide range of medical conditions, particularly for rare and intractable diseases where innovative and effective treatments are highly sought after.
The core of this agreement is the integration of strengths between the two organizations. Wonkwang University Hospital brings its specialized clinical experience to be combined with EHL BIO's internationally recognized stem cell isolation and culture technology. Together, they aim to develop high-quality and safe treatment solutions for patients both in South Korea and globally.
Stem Cell and Immune Cell Research for Enhanced Quality of Life
Under this collaboration, EHL BIO and Wonkwang University Hospital will focus on clinical research using both stem cells and immune cells, innovations currently in the medical development stage aimed at overcoming the limitations of traditional treatments. Stem cells have the ability to differentiate into various tissues to repair damage, while immune cells play a crucial role in eliminating foreign substances and maintaining bodily balance.
With EHL BIO's GMP-certified quality management system, capable of producing up to 6,000 lots per year, and the expertise of over 85 researchers, this collaborative project with Wonkwang University Hospital is ensured to meet international standards. It operates under the regulations of South Korea's Advanced Regenerative Bio Act, ensuring safety and quality.
Combining clinical expertise with advanced cell technology is the key to treating diseases that are currently difficult to overcome.
Aiming for Leadership in Biotechnology
This collaboration is not only an expansion of the medical network but also reinforces the vision of CEO MD Hong-gi Lee to benefit humanity through advanced regenerative medicine. The alliance of partners equipped with both modern medical equipment and research technology will ensure smooth and rapid clinical operations.
In addition to Wonkwang University Hospital, EHL BIO maintains a network of over 100 partner hospitals in Korea and more than 50 globally, demonstrating stability and trust in our cell therapy innovations. We are committed to developing healthcare and anti-aging solutions to sustainably improve quality of life and extend longevity for our clients.
Service Procedure for Thai Patients
For interested parties from Thailand, EHL Thailand provides a dedicated Thai coordination team. The service consists of 6 clear steps: starting with an online consultation, followed by a medical document evaluation for travel planning. Upon arrival in Korea, a physical examination and cell collection will take place at the EHL Cell Clinic in Apgujeong.
Cell samples are then cultured in a Class 100 GMP center with rigorous quality control before being administered according to the plan set by the EHL medical team. After the procedure and returning to Thailand, our team continues to monitor results to ensure effectiveness and an improved quality of life for every client.
Frequently asked questions
What types of diseases does the collaboration with Wonkwang University Hospital focus on?
It focuses on clinical research for treating rare and intractable diseases using stem cells and immune cells.
What is the safety level of EHL BIO's cell culture technology?
We utilize Class 100 GMP manufacturing facilities and are certified as a Human Cell Management Business by the Korean MFDS.
Can Thai people participate in treatment programs under this partner network?
Yes, you can consult through EHL Thailand, which provides coordination from document evaluation to post-treatment follow-up after returning home.
Related conditions
Based on EHL BIO information: EHL BIO · EHL BIO · EHL BIO · EHL BIO. Each care plan follows an individual EHL assessment.
